IBC’s 7th Annual Generics Asia Summit is the longest running conference to bring together the East and West together to discuss strategies in branded generics.

As innovators continue honing their defensive strategies in the West while focusing growth in the East, generic companies in Asia are now strategically positioned to provide local knowledge or compete for position in established but also increasingly emerging markets. In this 7th Annual Summit: Branded Generics Strategy Asia attention will shift towards how innovators, generics companies and investors will play in future markets. Be privy to the latest industry knowledge, open and in-depth dialogues and insights from regional and global leaders. In order to succeed in the ever competitive generics pie, networking and knowledge is key.

• FOCUS on industry partnering to compete post patent
• NEW – spotlight technology sessions eg latest drug delivery innovations such as inhalation, transdermal, injection
• NEW – Advanced formulation strategies and techniques, expedited or new approvals
• EMERGING revenue streams eg expanding services in co-development, contract manufacturing
• MORE updates - Addressing pricing and reimbursement policies across Asia
• Featuring how Big Pharma is managing post blockbuster patent expiries
• REVISED FORMATS with illuminating debate from dual Pharma and Generic perspectives – sustainable strategies in the generic race
• EXPANDED coverage of developments in generics to be of interest to API, formulation, manufacturing

• Rajesh Kumar, Generics Director, South East Asia & Indochina, Sanofi-Aventis
• Jamaludin Elis , Commercial Director, Pharmaniaga Marketing Sdn Bhd
• Dr Mandar Kodgule, Associate Vice President & Head, Global IP & Strategic Planning, Wockhardt Ltd
• Dr Ron Tomer, Vice President, Unipharm
• Khalid Mahmood , Managing Director & Chief Executive Officer, Getz Pharma (Pvt) Limited

“ Eye Opening & relative to industry” Chen, Eisai (M) Sdn Bhd

“ Networking and excellent presentations” Runkel, Actavis

“This conference provides a good outlook for the generic industry, especially in the SEA context” Heng, Novozymes

“There was great interaction between speakers & audience” Cher, Business Monitor International